Efficacy and safety of neoadjuvant immunotherapy for hepatocellular carcinoma
10.3760/cma.j.cn112139-20220408-00150
- VernacularTitle:肝细胞癌免疫新辅助治疗的有效性和安全性分析
- Author:
Yongxiang XIA
1
;
Hui ZHANG
;
Feng ZHANG
;
Xiangcheng LI
;
Dawei RONG
;
Weiwei TANG
;
Hengsong CAO
;
Jie ZHAO
;
Ping WANG
;
Liyong PU
;
Xiaofeng QIAN
;
Feng CHENG
;
Ke WANG
;
Lianbao KONG
;
Chuanyong ZHANG
;
Donghua LI
;
Jinhua SONG
;
Aihua YAO
;
Xiaofeng WU
;
Chen WU
;
Xuehao WANG
Author Information
1. 南京医科大学第一附属医院肝胆中心 中国医学科学院肝移植重点实验室 国家卫生健康委员会活体肝移植重点实验室，南京210000
- Keywords:
Liver neoplasms;
Hepatectomy;
Immune checkpoint inhibitors;
Targeting therapy;
Neoadjuvant therapy
- From:
Chinese Journal of Surgery
2022;60(7):688-694
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the surgical safety and efficacy of preoperative neoadjuvant therapy with immune checkpoint inhibitors combined with anti-angiogenic drugs in patients with China liver cancer staging(CNLC)-Ⅱb and Ⅲa resectable hepatocellular carcinoma.Methods:The data of 129 patients with Ⅱb and Ⅲa hepatocellular carcinoma who underwent surgery at the First Affiliated Hospital of Nanjing Medical University from January 2018 to December 2020 were analyzed. All patients were divided into two groups: the neoadjuvant therapy group( n=14,13 males and 1 female,aged (55.4±12.6)years(range:34 to 75 years)) received immune combined targeted therapy before surgery,immune checkpoint inhibitor camrelizumab was administered intravenously at a dose of 200 mg each time,every 2 weeks for 3 cycles,anti-angiogenesis drug apatinib was taken orally and continuously with a dose of 250 mg for 3 weeks and the conventional surgery group( n=115,103 males and 12 females,aged (55.8±12.0)years(range:21 to 83 years)) did not receive antitumor systemic therapy before surgery. There were 3 patients with CNLC-Ⅱb,11 with CNLC-Ⅲa in the neoadjuvant group;28 patients with CNLC-Ⅱb,87 with CNLC-Ⅲa in the conventional group. Student′s t test or rank-sum test was used to compare the differences between two groups for quantitative data, Fisher′s exact probability method was used to compare the differences of proportions between two groups, and Log-rank test was used to compare survival differences between two groups. Results:The 1-year recurrence rate in the neoadjuvant group was 42.9%,and the 1-year recurrence rate in the conventional group was 64.0%,with a statistically significant difference between the two groups(χ2=3.850, P=0.050);The 1-year survival rate in the neoadjuvant group was 100% and that in the conventional group was 74.2%,with a statistically significant difference between the two groups(χ2=5.170, P=0.023). According to the stratified analysis of the number of tumors,for single tumor,the 1-year recurrence rate in the neoadjuvant group was 25.0%,and that in the conventional surgery group was 71.0%,and the difference between the two groups was statistically significant(χ2=5.280, P=0.022). For multiple tumors, the 1-year recurrence rate in the neoadjuvant group was 66.7%,and the 1-year recurrence rate in the conventional surgery group was 58.9%,with no significant difference between the two groups(χ2=0.110, P=0.736). The operative time,intraoperative blood loss,and postoperative hospital stay in the neoadjuvant group were similar to those in the conventional group,and their differences were not statistically significant. Conclusions:Immune checkpoint inhibitors combined with anti-angiogenic targeted drugs as a neoadjuvant therapy for resectable hepatocellular carcinoma can reduce the 1-year recurrence rate and improve the 1-year survival rate,especially for those with solitary tumor. Limited by the sample size of the neoadjuvant group,the safety of immune combined targeted therapy before surgery cannot be observed more comprehensively,and further studies will be explored.
